Testagen
Also known as: KEDG · Lys-Glu-Asp-Gly · H-Lys-Glu-Asp-Gly-OH · lysyl-glutamyl-aspartyl-glycine · Testagen (Cytogen/Cytogen-series synthetic peptide)
Research focus
Marketed for the testicular/reproductive system; in the actual indexed literature, studied as an anterior-pituitary-derived peptide tested on endocrine tissue (thyroid, thymus) and, in vitro, on DNA/histone binding.
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
No Human Data
Origin
Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly, abbreviated KEDG) associated with Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, the Russian group behind the broader family of short "Cytogen"/"Cytomax" peptide bioregulators (Epitalon, Pinealon, Bronchogen, Vesugen and others). Like the rest of that family, it was developed under the group's working hypothesis that very short peptides "designed" from the amino-acid composition of organ peptide extracts ("cytomedins") could reproduce tissue-regulating effects. Despite the consumer-marketing label "Testagen" (which implies a testicular/reproductive role), the indexed peer-reviewed literature does not describe KEDG as a testis peptide: where its biology is studied, it is treated as a peptide modeled on anterior-pituitary extracts and tested on endocrine tissue. The KEDG sequence itself is confirmed in independent peer-reviewed work — including a 2025 materials-chemistry study that synthesized "testagen (KEDG)" as H-Lys-Glu-Asp-Gly-OH and a 2011 Khavinson-group cell-biology paper that lists testagen as Lys-Glu-Asp-Gly. We flag the testis/reproductive framing as a marketing claim that the published record does not support.
Plain-language summary
Testagen is a lab-made four-amino-acid peptide (Lys-Glu-Asp-Gly) from the same Russian research lineage as Epitalon and the other "bioregulator" peptides. Its name suggests it does something for the testes or male reproductive health, but that idea does not appear anywhere in the published scientific literature we could find. The handful of real studies that exist are either test-tube experiments showing the peptide can enter cells and stick to DNA, or animal experiments in birds where it was used as a pituitary-type peptide affecting the thyroid and thymus — not the testes. There are no human studies of any kind. Anything sold online as "Testagen" for reproductive or anti-aging benefit is being marketed well beyond what the evidence shows.
Claimed mechanism (as reported)
Vendors claim Testagen supports testicular and reproductive function, but no published mechanism for any such effect exists. In the Khavinson group's own model, short peptides like KEDG are proposed to penetrate the cell and nucleus and bind DNA and histones in a sequence-specific way, thereby reportedly influencing gene expression; in one in-vitro study testagen appeared to preferentially associate with CAG-containing oligonucleotide sequences. This DNA/histone-binding mechanism is hypothesis-stage, supported only by in-vitro fluorescence-quenching and cell-culture work from a small set of collaborating groups, and has not been tied to any reproductive outcome. Mechanism remains entirely unproven in humans.
Evidence summary
No human studies of Testagen exist in the peer-reviewed English-language literature as of 2026 — no randomized trials, no open-label cohorts, nothing. The total real evidence base is thin and almost entirely preclinical: a small number of in-vitro DNA- and histone-binding experiments from the Khavinson group (which test testagen alongside several other short peptides), and a set of animal studies in hypophysectomized birds in which Lys-Glu-Asp-Gly is used as an anterior-pituitary peptide acting on the thyroid and thymus. Notably, the published biology does not support the marketed "testis/reproductive" positioning at all. No independent replication of any functional claim exists, and the relevant work comes from a small cluster of collaborating Russian institutions. Treat any reproductive, hormonal, or anti-aging benefit as unproven.
What the research reports
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
Grade DFedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF · Biochemistry (Moscow) / Biokhimiia · 2011
Reported finding: Fluorescein-labeled testagen (Lys-Glu-Asp-Gly), alongside epithalon and pinealon, reportedly entered the cytoplasm, nucleus and nucleolus of HeLa cells and showed sequence-specific binding to labeled oligonucleotides — testagen appearing to associate preferentially with CAG-containing sequences. This is a binding/penetration observation only; it demonstrates no reproductive or therapeutic effect.
Sample: Laboratory assays (HeLa cells; labeled oligonucleotides/DNA) — no organisms or subjects
Methodology: D — in-vitro / cell-culture mechanism study; testagen tested only as one of several peptides; no functional or disease endpoint
Limitations: In-vitro only; single research group; binding inferred from fluorescence quenching; no link to any physiological outcome; no human relevance established.
Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens
Grade CKuznik BI, Pateyuk AV, Rusaeva NS (and related reports by the same group) · Bulletin of Experimental Biology and Medicine (with companion papers in Advances in Gerontology / Uspekhi Gerontologii) · 2008–2013
Reported finding: Administration of Lys-Glu-Asp-Gly to hypophysectomized birds was reported to partially restore thyroid and thymus structure and normalize thyroid-hormone and immune/hemostatic parameters, framed as an anterior-pituitary peptide effect. Reported without independent replication and with no reproductive endpoint.
Sample: Groups of chickens/hens (typically small per-group animal cohorts; exact n varies by report)
Methodology: C/D — small animal studies, single collaborating group, used as a pituitary (not testis) peptide; limited blinding and reporting
Limitations: Animal model only; small samples; single research lineage; outcomes are endocrine/immune, not reproductive; no human data; effects unconfirmed externally.
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides
Grade DFedoreyeva LI, Smirnova TA, Kolomijtseva GYa, Khavinson VKh, Vanyushin BF · Biochemistry (Moscow) / Biokhimiia · 2013
Reported finding: Short peptides including Lys-Glu-Asp-Gly (testagen) were reported to bind FITC-labeled wheat histones and histone–DNA complexes in a site-specific manner, offered as support for a proposed epigenetic gene-regulation mechanism. This is a binding observation in a plant/in-vitro system with no demonstrated human or reproductive relevance.
Sample: Laboratory assays (wheat histones, labeled oligonucleotides) — no subjects
Methodology: D — in-vitro biophysical binding study; testagen one of several peptides; no physiological endpoint
Limitations: In-vitro, non-mammalian model; single group; mechanism inferred from fluorescence modulation; no functional, animal, or human outcome.
The inhibitory effect and adsorption properties of Testagen peptide on copper surfaces in saline environments (sequence-confirming, non-biomedical)
Grade CDobritescu A, Samide A, Cioatera N et al. · Molecules · 2025
Reported finding: Independently synthesized 'testagen (KEDG)' as H-Lys-Glu-Asp-Gly-OH and characterized it as a copper-corrosion inhibitor. Useful here only because it independently corroborates the Lys-Glu-Asp-Gly sequence and 'Testagen' naming; it makes no biomedical or reproductive claim.
Sample: Electrochemical and computational measurements — not a biological study
Methodology: N/A (biomedical) — materials-chemistry study; included only to confirm the KEDG identity/sequence
Limitations: Not a biological or clinical study; no bearing on safety or efficacy in humans; relevant only for sequence verification.
Administration reported in studies
There are no human administration data. In the in-vitro work, testagen was applied directly to cultured cells or to isolated DNA/histone preparations at laboratory concentrations. In the animal work, Lys-Glu-Asp-Gly was injected into hypophysectomized birds over multi-week courses (e.g., roughly 40 days in some reports) as part of an endocrine experiment — not as a reproductive protocol and not at any defined human-equivalent dose. No validated route, dose, or schedule for humans has ever been published. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
No human safety data exist. No published clinical trials, pharmacokinetic studies, toxicology packages, or adverse-event reporting in humans could be identified. The limited animal and in-vitro work was not designed to characterize safety, and short-peptide stability, absorption, and long-term effects in humans are unknown. The absence of reported harm is not evidence of safety — it reflects the absence of study. Material sold online as "Testagen" is unregulated research chemical of unverified identity and purity.
US legal status
Not FDA-approved for any use. Not on the FDA 503A compoundable bulk drug substances list, and not legally compoundable for human clinical use in the United States. Sold online only as a "research chemical" — vendors in that channel are unregulated and are not verified by TPC. TPC takes no vendor money and does not endorse any source.
Open research questions
- ? Does any peer-reviewed evidence — at any level — support the marketed 'testis/reproductive' positioning, given that the published biology treats Lys-Glu-Asp-Gly as a pituitary/endocrine peptide and never as a testicular agent?
- ? Can the in-vitro DNA- and histone-binding observations be independently replicated outside the Khavinson/Vanyushin group, and do they translate to any measurable effect in a living mammal?
- ? What are the basic pharmacokinetics in humans — is an orally or subcutaneously administered tetrapeptide even absorbed intact and bioavailable, or is it rapidly degraded?
- ? What is the human safety profile across single and repeated dosing, including long-term endpoints, given that no toxicology or clinical-safety data exist?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →